Abstract
A therapeutic trial with methenolone (Primobolan) in 19 consecutive patients with different types of refractory anemia was reported. The remission frequencies were the following: panctyopenia 3/6, bicytopenia 2/4, refractory anemia with hyperplastic marrow 1/5 and myelofibrosis 1/4. There was no obvious prolongation of survival in the patients responding. Side-effects were negligible.

This publication has 10 references indexed in Scilit: